Pronóstico del mercado europeo de terapias contra el cáncer de mama hasta 2030 – Análisis regional – por terapia farmacológica [terapia farmacológica dirigida (abemaciclib, ado-trastuzumab emtansina, palbociclib, trastuzumab y otras terapias farmacológicas objetivo), terapia farmacológica hormonal (moduladores selectivos de los receptores de estrógeno, inhibidores de la aromatasa, y reguladores negativos selectivos de los receptores de estrógeno), quimioterapia e inmunoterapia/terapia biológica], tipo de cáncer de mama (receptor hormonal, HER2+ y cáncer de mama triple negativo) y canal de distribución (farmacias hospitalarias, farmacias y farmacias minoristas, y farmacias en línea) X

BMIRE00029748 | Pages: 106 | Pharmaceuticals | Mar 2024 | Type: Regional | Status: Published
El mercado europeo de terapias contra el cáncer de mama se valoró en 8.446,96 millones de dólares en 2022 y se espera que alcance los 16.836,17 millones de dólares en 2030; se estima que crecerá a una tasa compuesta anual del 9,0% entre 2022 y 2030.

Un mayor apoyo del gobierno y de organizaciones privadas impulsa el mercado europeo de terapias contra el cáncer de mama

Los gobiernos de varios países reconocen la importancia de abordando el cáncer de mama y están implementando políticas para mejorar el acceso a tratamientos efectivos. Muchos gobiernos y organizaciones privadas han aumentado la financiación para la investigación y el desarrollo de terapias contra el cáncer de mama, lo que ha dado como resultado el desarrollo de medicamentos y terapias innovadoras. La Iniciativa de la Comisión Europea sobre el Cáncer de Mama (ECIBC) ofrece atención básica de calidad, universalmente accesible, en todos los niveles. La misión de ECIBC es brindar a las mujeres y a los profesionales de la salud asesoramiento imparcial e imparcial sobre detección y atención basado en las investigaciones científicas más recientes. El aumento de la inversión en investigación ha permitido a las empresas farmacéuticas explorar nuevas opciones de tratamiento y desarrollar terapias muy específicas y eficaces para pacientes con cáncer de mama.

Varios organismos gubernamentales de todo el mundo también están tomando medidas para mejorar el acceso a estos tratamientos mediante la implementación de políticas de reembolso e iniciativas de atención médica que cubran el costo de la terapia contra el cáncer de mama para los pacientes. Esto significa que más pacientes pueden costear estos tratamientos y tener acceso a los últimos avances en la terapéutica del cáncer de mama. El mayor apoyo gubernamental también ha creado un entorno de mercado favorable para los proveedores de atención médica. Con más financiación y recursos disponibles, los proveedores de atención médica pueden ofrecer a sus pacientes una gama más amplia de opciones de tratamiento. Esto mejora los resultados de los pacientes y permite a los proveedores de atención médica seguir siendo competitivos en el mercado. En general, el mayor apoyo de los gobiernos y organizaciones privadas a la terapia contra el cáncer de mama ha impulsado la innovación, lo que ha dado lugar a tratamientos nuevos y mejores. También ha mejorado el acceso a estos tratamientos, beneficiando a más pacientes. Esto presenta una oportunidad importante para el crecimiento del mercado europeo de terapias contra el cáncer de mama, ya que las empresas farmacéuticas y los proveedores de atención médica continúan invirtiendo en actividades de investigación y desarrollo y ampliando sus ofertas para satisfacer la creciente demanda.

Descripción general del mercado europeo de terapias contra el cáncer de mama

El mercado europeo de terapias contra el cáncer de mama está segmentado en Alemania, el Reino Unido, Francia, Italia, España y el resto de Europa. El cáncer de mama es un tipo común de cáncer en el Reino Unido. Según datos del Servicio Nacional de Salud (NHS), aproximadamente una de cada siete mujeres es diagnosticada con cáncer de mama durante su vida en Gran Bretaña. Cada año, aproximadamente 55 000 mujeres son diagnosticadas con cáncer de mama.

La mayor demanda por parte de la industria médica para tratar a pacientes con cáncer de mama con terapias novedosas ha llevado a una mayor inversión en I+D, impulsando el crecimiento del mercado. Breast Cancer Now es el mayor financiador dedicado a la investigación del cáncer de mama en el Reino Unido. A la fecha ha invertido US$ 308,01 millones (

Table of Content

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Breast Cancer Therapeutics Market - Key Industry Dynamics

4.1 Key Market Drivers

4.1.1 Growing Burden of Breast Cancer

4.1.2 Launch of Several Diagnostics and Screening Programs

4.2 Key Market Restraints

4.2.1 High Cost of Diagnosis and Treatment

4.3 Key Market Opportunities

4.3.1 Increased Support from Government and Private Organizations

4.4 Key Future Trends

4.4.1 Increasing Use of Personalized Medicine

4.5 Impact Analysis:

5. Breast Cancer Therapeutics Market - Europe Market Analysis

5.1 Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

6. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy

6.1 Overview

6.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)

6.3 Targeted Drug Therapy

6.3.1 Overview

6.3.2 Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.3.2.1 Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)

6.4 Hormonal Drug Therapy

6.4.1 Overview

6.4.2 Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.4.2.1 Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)

6.5 Chemotherapy

6.5.1 Overview

6.5.2 Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

6.6 Immunotherapy/ Biological Therapy

6.6.1 Overview

6.6.2 Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type

7.1 Overview

7.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)

7.3 Hormone Receptor

7.3.1 Overview

7.3.2 Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.4 HER2+ (human epidermal growth factor receptor 2)

7.4.1 Overview

7.4.2 HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Triple-Negative Breast Cancer

7.5.1 Overview

7.5.2 Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview

8.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)

8.3 Hospital Pharmacies

8.3.1 Overview

8.3.2 Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Drug Store and Retail Pharmacies

8.4.1 Overview

8.4.2 Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8.5 Online Pharmacies

8.5.1 Overview

8.5.2 Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Breast Cancer Therapeutics Market - Country Analysis

9.1 Europe Breast Cancer Therapeutics Market, Revenue and Forecast to 2030

9.1.1 Overview

9.1.2 Europe Breast Cancer Therapeutics Market, Breakdown, by key Country- Revenue (2022) (US$ Million)

9.1.3 Europe Breast Cancer Therapeutics Market, by Country, 2022 and 2030 (%)

9.1.3.1 UK

9.1.3.1.1 UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.1.2 UK: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.1.2.1 UK: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.1.2.2 UK: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.1.3 UK: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)

9.1.3.1.4 UK: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

9.1.3.2 Germany

9.1.3.2.1 Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.2.2 Germany: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.2.2.1 Germany: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.2.2.2 Germany: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.2.3 Germany: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)

9.1.3.2.4 Germany: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

9.1.3.3 France

9.1.3.3.1 France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.3.2 France: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.3.2.1 France: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.3.2.2 France: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.3.3 France: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)

9.1.3.3.4 France: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

9.1.3.4 Italy

9.1.3.4.1 Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.4.2 Italy: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.4.2.1 Italy: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.4.2.2 Italy: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.4.3 Italy: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)

9.1.3.4.4 Italy: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

9.1.3.5 Spain

9.1.3.5.1 Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.5.2 Spain: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.5.2.1 Spain: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.5.2.2 Spain: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.5.3 Spain: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)

9.1.3.5.4 Spain: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

9.1.3.6 Rest of Europe

9.1.3.6.1 Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.6.2 Rest of Europe: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.6.2.1 Rest of Europe: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.6.2.2 Rest of Europe: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)

9.1.3.6.3 Rest of Europe: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)

9.1.3.6.4 Rest of Europe: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Breast Cancer Therapeutics Market-Industry Landscape

10.1 Overview

10.2 Growth Strategies in Breast Cancer Therapeutics Market

10.3 Organic Growth Strategies

10.3.1 Overview

10.4 Inorganic Growth Strategies

10.4.1 Overview

11. Company Profiles

11.1 Eli Lilly and Co

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Eisai Co Ltd

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 Novartis AG

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 AstraZeneca Plc

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 Pfizer Inc

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Gilead Sciences Inc

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 Merck & Co Inc

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 Teva Pharmaceutical Industries Ltd

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

11.9 Amgen Inc

11.9.1 Key Facts

11.9.2 Business Description

11.9.3 Products and Services

11.9.4 Financial Overview

11.9.5 SWOT Analysis

11.9.6 Key Developments

12. Appendix

12.1 About Us

12.2 Glossary of Terms

 

 

List of Tables

Table 1. Europe Breast Cancer Therapeutics Market Segmentation

Table 2. Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 3. Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 4. UK Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 5. UK Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 6. UK Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 7. UK Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)

Table 8. UK Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)

Table 9. Germany Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 10. Germany Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 11. Germany Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 12. Germany Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)

Table 13. Germany Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)

Table 14. France Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 15. France Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 16. France Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 17. France Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)

Table 18. France Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)

Table 19. Italy Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 20. Italy Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 21. Italy Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 22. Italy Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)

Table 23. Italy Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)

Table 24. Spain Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 25. Spain Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 26. Spain Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 27. Spain Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)

Table 28. Spain Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)

Table 29. Rest of Europe Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 30. Rest of Europe Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 31. Rest of Europe Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)

Table 32. Rest of Europe Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)

Table 33. Rest of Europe Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)

Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market

Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market

Table 36. Glossary of Terms, Breast Cancer Therapeutics Market

List of Figures

Figure 1. Europe Breast Cancer Therapeutics Market Segmentation, By Country

Figure 2. Europe Breast Cancer Therapeutics Market - Key Industry Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

Figure 5. Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)

Figure 6. Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 10. Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)

Figure 11. Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)

Figure 15. Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Europe Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)

Figure 19. Europe Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)

Figure 20. UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

Figure 21. Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

Figure 22. France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

Figure 23. Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

Figure 24. Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

Figure 25. Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)

Figure 26. Growth Strategies in Breast Cancer Therapeutics Market

1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe breast cancer therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in Europe breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440